Stem Cells

Research Summary: Autologous hematopoietic stem cell transplantation for multiple sclerosis: Long-term follow-up data from Norway Although not a new treatment approach, haematopoietic stem cell...

Research Summary: Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study The treatment of progressive multiple sclerosis remains an unmet need. ...

Written by Brett Drummond (MStranslate co-founder), in collaboration with Joey Lambert (MStranslate intern) Autologous haematopoietic stem cell transplantation (AHSCT) is an exciting, recently developed...

With the end of 2020 approaching (I don’t think anyone is going to miss it), we thought we would try out a new style of research update.  Generally, our articles are an in-depth look at a specific study...

EXCLUSIVE INTERVIEW At ECTRIMS Congress 2019, we had the privilege of interviewing Prof. Dimitrios Karussis (Neurologist, Hadassah Hospital) about the exciting results from his mesenchymal stem cell trial...

Over recent years, we have seen a large expansion in the number of available treatments for people living with relapsing-remitting multiple sclerosis (RRMS).  As well as this, we have recently seen a number...

Research Summary: CD34 defines melanocyte stem cell subpopulations with distinct regenerative properties Myelin repair or remyelination is considered by many, including an overwhelming majority of our...

Research Summary: Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A...

Recently, I’ve had the pleasure of talking to a number of different local multiple sclerosis support groups about multiple sclerosis (MS) and MS research.  These events generally involve me giving a small...

Research Summary: High dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS The 5 year results of the HALT-MS trial were today published in Neurology.  The HALT-MS clinical trial has...